Intestinal Carcinoma — Trials

Intestinal Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1,268 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 409
Recruiting: 235
Ph III recruiting: 16
Growth YoY: +6%
Industry share: 18%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (150)

clinicaltrialsPublishedShowing 1–11 of 11 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05610163	Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response(JANUS)	active not recruiting	Phase 2 / Phase 3	760	Alliance for Clinical Trials in OncologyOTHER	2	Sep 25, 2026	clinicaltrials
NCT04444921	EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients	active not recruiting	Phase 3	205	National Cancer Institute (NCI)